Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence guidance

This document provides product-specific guidance on the demonstration of budesonide, prolonged release tablets, 9 mg product-specific bioequivalence guidance.

Keywords: Bioequivalence, generics, budesonide

 

Current version

Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence guidance

Adopted Reference Number: EMA/CHMP/219378/2024 Legal effective date: 01/09/2025

Document history

Budesonide, prolonged release tablets, 9 mg product-specific bioequivalence guidance

Draft: consultation closed Consultation dates: 25/06/2024 to 30/09/2024 Reference Number: EMA/CHMP/219378/2024 Summary:

Comments should be provided using this EUSurvey form . For any technical issues, please contact the EUSurvey Support.